We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

KKR Injects $60M In Slayback Pharma

Law360, New York (January 6, 2017, 1:03 PM EST) -- Pharmaceutical research and development company Slayback Pharma LLC said Thursday that it has received a $60 million investment from private equity giant KKR & Co. to help accelerate the development of its portfolio of complex generic drugs.

As part of the deal, KKR’s Ali Satvat and Neel Varshney will join Slayback’s board of directors, according to a statement announcing the commitment. Slayback CEO Ajay Singh said the relationship will benefit the company beyond the capital injection.

“In addition to being a highly regarded long-term capital partner,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.